Glenmark Pharma - Stable Q3 Numbers; Margin Expansion To The Fore: ICICI Direct 
A techncian at Glenmark Pharma’s R&D lab (Image: Company website)

Glenmark Pharma - Stable Q3 Numbers; Margin Expansion To The Fore: ICICI Direct 

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Glenmark Pharmaceutical Ltd.’s Q3 revenues grew 1.9% YoY to Rs 2787 crore with 11.8% YoY growth in domestic sales to Rs 882 crore supported by Fabiflu (favipiravir) sales being partly offset by 2.4% decline in U.S. to Rs 780 crore.

Europe business grew just 1.4% YoY to Rs 313 crore amid enhanced lockdown measures.

Rest of World markets de-grew 1.6% YoY to Rs 336 crore whereas active pharmaceutical ingredient segment grew 22.1% YoY to Rs 320 crore.

Ebitda margins improved 293 basis points YoY to 19.0% mainly due to lower other expenditure, better gross margins.

Click on the attachment to read the full report:

ICICI Direct Glenmark Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.